<DOC>
	<DOCNO>NCT00293540</DOCNO>
	<brief_summary>This study determine hormone receptor positive premenopausal metastatic breast cancer patient undergo removal ovary mid-luteal versus mid-follicular phase longer survival .</brief_summary>
	<brief_title>Luteal v Follicular Surgical Oophorectomy Tamoxifen Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description>Rationale : Previous research suggest woman ovary remove part treatment breast cancer may live long ovarian surgery perform luteal phase ( last 14 day menstrual cycle ) rather follicular phase ( first 14 day menstrual cycle ) . The current study evaluate important research question premenopausal woman metastatic hormone receptor-positive breast cancer treat surgery tamoxifen . Purpose : The purpose research find premenopausal woman breast cancer spread part body live long ovary remove second half menstrual cycle . This study compare long woman live ovary remove first half menstrual cycle ( follicular phase ) long woman live ovary remove second half menstrual cycle ( luteal phase ) . Tamoxifen also give study participant . Treatment : Study participant test perform advance surgery remove ovary . Surgery perform within four week test . The exact day determine study participant 's menstrual history process call randomization , random decision making process determine study participant surgery first second half menstrual cycle . On day surgery , blood take immediately prior surgery three hour surgery hormone test . After surgery , study participant give tamoxifen oral pill daily consumption . Study participant ask return hospital every two month test distribution additional tamoxifen tablet . Treatments discontinue disease progression unacceptable adverse effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Estrogen receptor progesterone receptor positive breast cancer Premenopausal regular menstrual cycle Current oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>secondary</keyword>
	<keyword>Hormone Receptor-Positive Breast Cancer</keyword>
</DOC>